Comprehensive profiing of clinical JAK inhibitors in myeloproliferative neoplasms
Comprehensive profiing of clinical JAK inhibitors in myeloproliferative neoplasms Overall design: HEL cells were treated in duplicate for 4 hour or 48 hours with DMSO control or 500nM of JAK inhibitors